Auro Laboratories Ltd
Auro Laboratories Ltd (AUROLAB) last reported results for the quarter ended Sep 2025, with sales of ₹8.84 crore and net profit of ₹0.72 crore. The stock last traded at ₹234, a market capitalisation of ₹146 crore, on a P/E of 66.3. Over the past 52 weeks the stock has ranged between ₹159 and ₹317. Figures are as of 6 Oct 2026 and are not real time.
Auro Laboratories Ltd share price and key metrics
- Current price
- ₹234
- Market cap
- ₹146 cr
- Stock P/E
- 66.3
- Book value
- ₹69.9
- ROE
- 4.28%
- ROCE
- %
- Dividend yield
- 0.00%
- 52w high / low
- 317/159
Metrics as of 6 Oct 2026. Not real time.
Track Auro Laboratories Ltd
Cruxal reads every Auro Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Auro Laboratories Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- 18%
- 5 Years
- 12%
- 3 Years
- 24%
- 1 Year
- 5%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 4%
Auro Laboratories Ltd quarterly results
| ₹ crore | Sep 2024 | Jun 2025 | Sep 2025 |
|---|---|---|---|
| Sales | 3.1 | 2.77 | 8.84 |
| Expenses | 2.38 | 2.74 | 6.49 |
| Operating profit | 0.72 | 0.03 | 2.35 |
| OPM % | 23.23% | 1.08% | 26.58% |
| Other income | 0.31 | 0.42 | 0.98 |
| Interest | 0.28 | 0.28 | 0.96 |
| Depreciation | 0.27 | 0.27 | 0.65 |
| Profit before tax | 0.48 | -0.1 | 1.72 |
| Tax % | 25.00% | -0.00% | 58.14% |
| Net profit | 0.36 | -0.11 | 0.72 |
| EPS (₹) | 0.58 | -0.18 | 1.16 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Auro Laboratories Ltd annual results
| ₹ crore | Mar 2025 |
|---|---|
| Sales | 19.4 |
| Operating profit | 3.4 |
| OPM % | 17.53% |
| Net profit | 1.84 |
| EPS (₹) | 2.95 |
TTM is the trailing twelve months to the most recent quarter.
Auro Laboratories Ltd balance sheet
| ₹ crore | Mar 2025 | Sep 2025 |
|---|---|---|
| Equity capital | 6.23 | 6.23 |
| Reserves | 36.74 | 37.35 |
| Borrowings | 42.72 | 43.94 |
| Other liabilities | 13.41 | 23.25 |
| Total liabilities | 99.10 | 110.77 |
| Fixed assets | 21.05 | 76.84 |
| CWIP | 56.48 | 10.37 |
| Investments | 0.05 | 0.05 |
| Other assets | 21.52 | 23.51 |
| Total assets | 99.10 | 110.77 |
As reported by the company. Total assets equal total liabilities by construction.
Auro Laboratories Ltd operating ratios
| Per year | Mar 2025 |
|---|---|
| Debtor days | 176.67 |
| Inventory days | 145.45 |
| Days payable | 246.11 |
| Cash conversion cycle | 76.01 |
| Working capital days | -14.30 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Auro Laboratories Ltd shareholding pattern
Promoters held 52.40% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 52.15% | 52.15% | 52.17% | 52.17% | 52.17% | 52.17% | 52.17% | 52.40% |
| DIIs | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 47.84% | 47.84% | 47.82% | 47.82% | 47.82% | 47.80% | 47.82% | 47.58% |
| No. of shareholders | 9,266 | 9,265 | 9,102 | 8,916 | 8,860 | 8,640 | 8,405 | 8,315 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Auro Laboratories Ltd corporate filings
- Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 we wish to inform you that, the trading window for dealing in the securities of the company will remain closed w.e.f. ....Insider Trading / SASTlow impact
- Auro Laboratories Limited Reports Strong Q1 FY2027 Financial Performance with Significant YoY GrowthCompany Updatehigh impact
Cruxal's analysis: Auro Laboratories Limited reported a robust performance for the quarter ended June 30…
Read the full analysis - Auro Laboratories reports strong turnaround in Q1 FY2027 with net profit of 1.05 croreBoard Meetinghigh impact
Cruxal's analysis: Auro Laboratories Limited has reported a significant financial turnaround for the quarter…
Read the full analysis - Auro Laboratories Limited Announces Successful Conclusion of 37th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Auro Laboratories Limited has successfully concluded its 37th Annual General Meeting held…
Read the full analysis - Auro Laboratories Limited Concludes 37th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Auro Laboratories Limited has successfully concluded its 37th Annual General Meeting held…
Read the full analysis - Auro Laboratories Limited schedules Board Meeting for August 14, 2026, to approve Q1 FY2027 financial resultsBoard Meetinglow impact
Cruxal's analysis: Auro Laboratories Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.